Skip to main content
×
Login
Submit a Manuscript
Home
Journal
Current Issue
Archive
For Authors
Column Series
Research & Insight
Special Reports
Subscribe
Resources
Blogs
Expert Insights
Latest News
Pathways Beyond Oncology
Topics
Comparative Effectiveness Research
Cost-Effectiveness Research
COVID-19 Updates
Guideline Updates
Health Economics and Outcomes Research
Health Technology
Real-World Data
Reimbursement
Value-Based Care
Specialties
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Biosimilars
Bladder Cancer
Breast Cancer
CAR-T Therapies
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Immuno-Oncology
Kidney Cancer
Liver Cancer
Lung Cancer
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Supportive Care
Excellence Forums
Mantle Cell Lymphoma Excellence Forum
Conferences
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ACCC Annual Meeting & Cancer Center Business Summit
ASCO Genitourinary Cancers Symposium
ASH Annual Meeting and Exposition
Oncology CME
About
About Us
Contact
Diffuse Large B-Cell Lymphoma
Featured
News
ASH Choosing Widely Recommendations Impact Frequency of Surveillance Imaging in DLBCL
The rate of surveillance imaging of survivors of DLBCL decreased after the American Society of Hematology (ASH) Choosing Wisely campaign.
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation…
Conference Coverage
Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and…
Conference Coverage
Polatuzumab Vedotin Plus Bendamustine-Rituximab Cost-Effective for DLBCL
Study results show polatuzumab vedotin plus bendamustine-rituximab is cost-effective in comparison to bendamustine-…
News
Real-World CAR-T Therapy Toxicity in Patients With DLBCL
More studies exploring real-world experience and data are necessary and will help define and refine management of…
News
ASH Choosing Widely Recommendations Impact Frequency of Surveillance Imaging in DLBCL
Real-World CAR-T Therapy Toxicity in Patients With DLBCL
Outcomes of CAR-T vs Alternate Therapies for DLBCL in the Real-World Setting
New Standard Treatment Approach for Patients With DLBCL
Guideline Updates
NCCN B-Cell Lymphomas Guideline Features Therapy Updates in Follicular Lymphoma, DLBCL
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top